Month: February 2023

  Sanofi announces change in R&D leadership Paris, February 13, 2023. Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He helped reshape Sanofi’s discovery and development of therapeutics, focusing efforts on first and best in class medicines that have the potential to transform the practice of medicine and improve the lives of people with serious diseases, whilst managing the integration and development of new technology platforms and partnerships, and driving R&D productivity. In 2023, Sanofi will launch two first or best-in-class medicines that will address...

Novaturas Group, the leader in the Baltic tourism market, was recognised at the Nasdaq Baltic Awards 2023 as the company that did the best job overcoming recent challenges and managing market change. Novaturas won the title of “The Challenge of the Year” – an award specially established by Nasdaq Vilnius for the most significant contribution to the development of the Lithuanian and Baltic capital markets. The income achieved in 2022 reflects the company’s balanced and targeted growth.   “There was no shortage of challenges last year – when the war started in Ukraine, tourism demand dropped significantly and the price of jet fuel increased drastically, which temporarily led to a considerable decrease in profitability. However, after a tough first half, we returned to the path of profitability by summer. In Q3 2022, EBITDA increased to EUR...

SkiStar AB (publ) today announces that Tobias Englund has been appointed as Unionen’s employee representative in the Board of Directors of SkiStar AB, effective from 9 May 2023. Following this decision, SkiStar’s Board of Directors thereafter includes – in addition to the seven members appointed by the general meeting of shareholders – two employee representatives, appointed by Unionen respectively Hotell- och Restaurangfacket. This information was submitted for publication, through the agency of the contact persons set out below, at 13 February 2023, 08.50 a.m. CET. Further information can be reached from: Stefan Sjöstrand, CEO, tel +46 (0)280 841 60.Anders Örnulf, CFO, tel +46 (0)280 841 60. SkiStar in brief SkiStar AB (publ) is listed on the Mid Cap list of the Nasdaq Stockholm exchange. The Group owns and operates mountain resorts...

Company announcement no. 08 As announced in company announcement no. 7/2023 (Annual Report 2022), Spar Nord is launching a share buyback programme of up to DKK 300 million with a view to reducing the Bank’s share capital by the shares acquired under the programme. Based on the closing price on 10 February 2023, this corresponds to around 2.5 million shares. The purpose of the share buyback is to optimise the Bank’s capital structure in accordance with the announced capital targets. At the end of Q4 2022, Spar Nord had a common equity tier 1 (CET1) ratio of 16.4%, while the own funds ratio was 20.9%. The effect of the share buyback programme is a deduction of 0.5 of a percentage point, which will be recognised in Q1 2023. Spar Nord pursues the goal of having a common equity tier 1 (CET1) ratio of 13.5% and an own funds ratio of 17.5%. The...

ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size is expected to reach US$9.26 billion by 2030.3 There is strong evidence for use of NSAIDs as first-line treatment for migraine, and celecoxib is in same class of agents, fast acting and has the potential to have the lowest GI side effects of all NSAIDs.2 ELYXYBTM has the potential to further expand Scilex’s non-opioid portfolio in broader acute pain indications and its acquisition establishes a growth platform for Scilex and fits within Scilex’s existing commercial team. The pain management therapeutics market size is estimated to reach US$ 101.27 billion by 2029 and growing at a CAGR of 4.3% from 2022 to 2030.4 ELYXYBTM is protected by six...

HII award winners at BEYA 2023 Seven employees from HII’s Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies divisions were recognized for achievements in the science, technology, engineering and math fields during the 37th annual Black Engineer of the Year Award (BEYA) STEM Conference.NEWPORT NEWS, Va., Feb. 11, 2023 (GLOBE NEWSWIRE) — Global all-domain defense provider HII (NYSE: HII) announced today that seven employees from its Newport News Shipbuilding, Ingalls Shipbuilding and Mission Technologies divisions were recognized for achievements in the science, technology, engineering and math fields during the 37th annual Black Engineer of the Year Award (BEYA) STEM Conference. The conference took place this week at the Gaylord Convention Center in National Harbor, Md. “I am incredibly proud of these...

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects OTX-TKI continued to be generally well tolerated with no drug-related serious adverse events through Month 10 Conference call to discuss results to be held on Monday, February 13 at 8:30 a.m. ET BEDFORD, Mass., Feb. 11, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 10-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal...